Education
About Us
Working with TipRanks
Follow Us
RUA Life Sciences (GB:RUA)
LSE:RUA
RUA Stock Chart & Stats
14.00p
-0.50p(-3.85%)
At close: 4:00 PM EST
14.00p
-0.50p(-3.85%)
Day’s Range― - ―
52-Week Range10.42p - 16.80p
Previous CloseN/A
Volume378.53K
Average Volume (3M)148.53K
Market Cap
£8.38M
Enterprise Value6.48M
Total Cash (Recent Filing)£3.25M
Total Debt (Recent Filing)£1.35M
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Jul 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding62,060,272
10 Day Avg. Volume90,619
30 Day Avg. Volume148,527
Financial Highlights & Ratios
PEG Ratio-75.00
Price to Book (P/B)1.03
Price to Sales (P/S)1.82
P/FCF Ratio-26.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£6.78M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA 40.81% revenue increase signals durable market traction for RUA's biomaterials and device-related offerings. Sustained top-line growth provides scale benefits, supports continued R&D and commercialization investment, and creates optionality to improve margins and funding sources over time.
High Gross MarginA 77.12% gross margin indicates strong product economics and likely differentiated, higher-value biomaterial products. This structural margin advantage gives room to absorb SG&A, fund clinical/commercial efforts, and supports long-term profitability if operating leverage is achieved.
Conservative Balance SheetLow leverage (debt/equity 0.14) and a strong equity ratio offer financial flexibility. A conservative capital structure reduces refinancing and interest risk, enabling the company to invest in growth, pursue partnerships, or fund product development without heavy debt servicing constraints.
Bears Say
Weak ProfitabilityMinimal net margin and negative EBIT reflect persistent operational profitability issues. Without converting revenue growth into operating profits, long-term sustainability is at risk; continued unprofitable operations may force cost cuts, reduce reinvestment, or require external financing.
Negative Operating Cash FlowNegative operating cash flow and falling free cash flow growth indicate the business does not yet generate sufficient cash from core operations. This constrains capacity to fund commercialization and R&D internally and increases reliance on external capital, raising liquidity and dilution risk.
Negative Return On EquityA negative ROE shows the company has not converted shareholder capital into positive returns historically. This structural shortfall can hinder future equity fundraising, weaken investor confidence, and signal inefficiencies in scaling or monetizing the business despite revenue gains.
RUA Life Sciences News
RUA FAQ
What was RUA Life Sciences’s price range in the past 12 months?
RUA Life Sciences lowest share price was 10.42p and its highest was 16.80p in the past 12 months.
What is RUA Life Sciences’s market cap?
RUA Life Sciences’s market cap is £8.38M.
When is RUA Life Sciences’s upcoming earnings report date?
RUA Life Sciences’s upcoming earnings report date is Jul 13, 2026 which is in 131 days.
How were RUA Life Sciences’s earnings last quarter?
RUA Life Sciences released its earnings results on Jan 30, 2026. The company reported 0.008p earnings per share for the quarter, beating the consensus estimate of N/A by 0.008p.
Is RUA Life Sciences overvalued?
According to Wall Street analysts RUA Life Sciences’s price is currently Overvalued.
Does RUA Life Sciences pay dividends?
RUA Life Sciences does not currently pay dividends.
What is RUA Life Sciences’s EPS estimate?
RUA Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RUA Life Sciences have?
RUA Life Sciences has 62,060,272 shares outstanding.
What happened to RUA Life Sciences’s price movement after its last earnings report?
RUA Life Sciences reported an EPS of 0.008p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -7.937%.
Which hedge fund is a major shareholder of RUA Life Sciences?
Currently, no hedge funds are holding shares in GB:RUA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RUA Life Sciences
RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as reaction injection molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.
Technical Analysis
Creo Medical
―
Genedrive
―
Inspiration Healthcare
―
OptiBiotix Health
―
Surgical Innovations
―
Options Prices
Currently, No data available
---